{
    "clinical_study": {
        "@rank": "19877", 
        "arm_group": {
            "arm_group_label": "ASP1585 group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a multi-center, open-labeled, non-comparative study to examine the safety and\n      efficacy of ASP1585 for long-term dosing in chronic kidney disease patients with\n      hyperphosphatemia not on dialysis."
        }, 
        "brief_title": "Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Renal Insufficiency", 
            "Hyperphosphatemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency", 
                "Hyperphosphatemia", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who completed study 1585-CL-0101 or new patients who meet following criteria\n\n          -  Chronic kidney disease patients (eGFR < 60 mL/min/1.73 m2)\n\n          -  Serum phosphorus measurement \u22674.6 mg/dl, <9.0 mg/dl\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with gastrointestinal surgery or enterectomy\n\n          -  Patients with severe cardiac diseases\n\n          -  Patients with severe constipation or diarrhea\n\n          -  Patients with a history or complication of malignant tumors\n\n          -  Patients with uncontrolled hypertension\n\n          -  Patients treated with parathyroid intervention"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742611", 
            "org_study_id": "1585-CL-0102"
        }, 
        "intervention": {
            "arm_group_label": "ASP1585 group", 
            "description": "oral", 
            "intervention_name": "ASP1585", 
            "intervention_type": "Drug", 
            "other_name": [
                "LY101", 
                "AMG223", 
                "bixalomer"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CKD", 
            "Not on dialysis", 
            "ASP1585", 
            "Bixalomer"
        ], 
        "lastchanged_date": "July 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time-course changes in serum phosphorus levels", 
            "safety_issue": "No", 
            "time_frame": "During 48 week treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742611"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Achievement rate of  the target range of serum phosphorus level", 
                "safety_issue": "No", 
                "time_frame": "During 48 week treatment"
            }, 
            {
                "measure": "Time to achieve the target range of serum phosphorus level", 
                "safety_issue": "No", 
                "time_frame": "During 48 week treatment"
            }, 
            {
                "measure": "Time-course changes in serum calcium levels", 
                "safety_issue": "No", 
                "time_frame": "During 48 week treatment"
            }, 
            {
                "measure": "Time-course changes in serum intact PTH (parathyroid hormone) levels", 
                "safety_issue": "No", 
                "time_frame": "During 48 week treatment"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, labo-tests and 12-lead ECGs", 
                "safety_issue": "No", 
                "time_frame": "During 48 week treatment"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}